Alsa Ventures is targeting a $150m final close for its inaugural biotherapeutics fund, which has already backed university-linked companies.
Morningside Ventures has thrown its weight behind the Harvard spinout, which hopes to develop bi-specific antibodies to treat age-driven cancers and inflammatory diseases.
The ETH Zurich software security spinout had raised at least $5.2m before it was purchased by Snyk yesterday for an undisclosed sum.
UCSF spinout Siolta Therapeutics picked up SymBiosis and Kirin Holdings in a round set to fund efficacy trials of its potential asthma treatment.
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Pureos Bioventures has backed five spinouts so far from its inaugural biotech-focused fund, which has reached its final close.
HBM Healthcare chipped in additional funding to bring University of Basel spinout Polyneuron's series A round to $39.7m.
Group 42 and BP Ventures have co-led a series C round for Caltech and Nasa spinout Beyond Limits, with $113m already closed.